Company Plans U.S. Future for Cannabis Drug

Company Plans U.S. Future for Cannabis Drug
Posted by CN Staff on February 28, 2005 at 08:03:17 PT
By Reuters
Source: Reuters
London -- Britain's GW Pharmaceuticals said on Monday it was accelerating plans to introduce its cannabis-based medicines into the United States as U.S. founder investors increased their stake in the business. At 1420 GMT, GW shares were up 5.3 percent at 129 pence.GW said it had engaged U.S.-based Apjohn Group LLC, a 10-member group of former major U.S. pharmaceutical company executives with extensive experience in U.S. clinical development, regulatory affairs and public policy.
It also said U.S. founder investors had put a further $4.8 million into the business, taking their stake to 9.62 percent from 7.79 percent.GW has had a roller-coaster ride with Sativex, an under-the-tongue cannabis spray to treat the symptoms of multiple sclerosis and neuropathic pain.The drug has won qualified approval in Canada, but is still awaiting a green light in Britain, where approval has been repeatedly delayed.Source: Reuters (Wire)Published: February 28, 2005Copyright: 2005 Reuters Related Articles & Web Site:GW Pharmaceuticals Pharma Buoyed by Hopes for Cannabis Drug Painkiller Hope for Cancer Patients 
Home Comment Email Register Recent Comments Help

Comment #4 posted by kaptinemo on February 28, 2005 at 13:19:45 PT:
1420 GMT their time is 2:20 their time
But given that space/time is curved, it's always 420 somewhere :)
[ Post Comment ]

Comment #3 posted by Sam Adams on February 28, 2005 at 12:09:42 PT
Look at the time of the stock price quote: could a mole have infiltrated the Reuters prohibitionist cabal?  A stoner has snuck into their office. He or she knew the old codger editors would never catch the significance of specifying the time of the stock quote.
[ Post Comment ]

Comment #2 posted by siege on February 28, 2005 at 09:55:40 PT
Tell Congress
Tell Congress to make drugs safer NOW! the first to pull out of the 'No Child Left Behind" Act.
[ Post Comment ]

Comment #1 posted by FoM on February 28, 2005 at 08:24:47 PT
GW To Take Cannabis Painkiller To America
By Mike Verdin, Times Online
 February 28, 2005 
 Shares in GW Pharmaceuticals have soared by 5 per cent after the company received the backing of American investors for a quest to take its cannabis-based painkiller to the US market. 
GW, which is close to winning approval for the drug, Sativex, in Canada, said that it had assembled a team of medical and regulatory consultants to pursue the product’s licensing in America."The US is the world’s most significant pharmaceutical market," Dr Geoffrey Guy, the GW chairman, said."Over the last few years, GW has been working to build a support base in the US and we are excited about the prospects of working alongside a range of experts to assist our efforts."The team included Apjohn Group, a Michigan-based pharmaceuticals consultancy, and unnamed "key medical opinion leaders", said GW, trailing an application for Sativex to the US Food and Drug Administration."The company considers that the breadth of data now available will enable initiation of discussions with the FDA," GW said.The move had prompted a group of key American investors to invest a further £2.5 million in GW, increasing their stake from 7.8 per cent to 9.6 per cent. The investment, to be spent largely on US operations, would be achieved through the issue of 2.0 million shares."We are delighted that our plans have met with such a positive response," Dr Guy said.GW shares stood 6p higher at 128.5p in afternoon trade. Copyright 2005 Times Newspapers Ltd.,,9068-1505283,00.html
[ Post Comment ]

Post Comment